Document is current
Any future updates will be listed below
-
Authors
Sakamoto, Masaki
Kuroda, Shinji https://orcid.org/0000-0002-4484-1253
Katayama, Tetsuya
Mikane, Yu
Hanzawa, Shunya
Kadowaki, Daisuke
Yoshida, Yusuke
Hamada, Yuki
Sugimoto, Ryoma
Yagi, Chiaki
Hashimoto, Masashi
Kanaya, Nobuhiko
Kakiuchi, Yoshihiko
Kikuchi, Satoru
Shigeyasu, Kunitoshi
Tazawa, Hiroshi
Kagawa, Shunsuke
Urata, Yasuo
Fujiwara, Toshiyoshi
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (JP24K02521)
Japan Society for the Promotion of Science (JP23K24407)
Japan Agency for Medical Research and Development (JP22ck0106569h0003)
- License Information
-
More Information
Article History
Received: 24 July 2025
Accepted: 20 November 2025
First Online: 18 December 2025
Declarations
:
: Y.U. is the President and CEO of Oncolys BioPharma, Inc., the manufacturer of OBP-702. H.T. and T.F. are consultants of Oncolys BioPharma, Inc. The remaining authors declare no competing interests.
